An investigative analysis of the business architecture behind pharma’s most durable profit model When Pfizer’s patent on atorvastatin expired in […]

The maturation of algorithmic discovery The pharmaceutical industry reached an inflection point in 2025 as artificial intelligence transitioned from a

The pharmaceutical industry is struggling with its own productivity. The cost of bringing a single new chemical entity to market

1. The Economics of Managed Exclusivity The pharmaceutical industry operates on a unique economic premise: huge upfront investment in research

Executive Summary The pharmaceutical sector currently faces a distinct legal friction where federal health policy conflicts with intellectual property statutes.

Executive Summary The biopharmaceutical and life sciences sectors face a central, defining strategic tension: the optimal allocation of capital between

In the high-stakes world of pharmaceuticals and biotechnology, intellectual property (IP) is no longer a simple legal instrument; it is

The Valuator’s Teacup: Why Pharma Forecasting Is a High-Stakes Riddle The Fundamental Challenge of Pharmaceutical Valuation The pharmaceutical and biotechnology

The term “patent cliff” has served as a powerful and often terrifying metaphor in the pharmaceutical industry. It paints a